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Retinoblastoma (RB), a childhood neoplasia of the retinoblasts, can occur unilaterally
or bilaterally, with one or multiple foci per eye. RB is associated with somatic loss of
function of both alleles of the tumor suppressor gene RB1. Hereditary forms emerge due
to germline loss of function mutations in RB1 alleles. RB has long been the prototypic
“model” cancer ever since Knudson’s “two-hit” hypothesis. However, a simple two-hit
model for RB is challenged by an increasing number of studies documenting additional
hits that contribute to RB development. Here we review the genetics and epigenetics
of RB with a focus on the role of small non-coding RNAs (microRNAs) and on novel
findings indicating the relevance of DNA methylation in the development and prognosis
of this neoplasia. Studies point to an elaborated landscape of genetic and epigenetic
complexity, in which a number of events and pahtways play crucial roles in the origin and
prognosis of RB. These include roles for microRNAs, inprinted loci, and parent-of-origin
contributions to RB1 regulation and RB progression. This complexity is also manifested
in the structure of the RB1 locus itself: it includes numerous repetitive DNA segments
and retrotransposon insertion elements, some of which are actively transcribed from the
RB1 locus. Altogether, we conclude that RB1 loss of function represents the tip of an
iceberg of events that determine RB development, progression, severity, and disease risk.
Comprehensive assessment of personalized RB risk will require genetic and epigenetic
evaluations beyond RB1 protein coding sequences.
Keywords: retinoblastoma, methylation, two-hit hypothesis, imprinting, Rb1, tumor suppressor, risk assessment,
childhood cancer
INTRODUCTION
Retinoblastoma (RB), a childhood neoplasia of the retinoblasts,
accounts for 2–4% of all childhood malignancies. Its prevalence
is around 1:15,000–1:20,000 (MacCarthy et al., 2006; Broaddus
et al., 2009), and can occur unilaterally or bilaterally, with one
or multiple foci per eye. RB can occur sporadically (∼60% of
cases) or be inherited (∼40% of cases) in an autosomal domi-
nant fashion (Cavenee et al., 1983; Lohmann and Gallie, 2004;
Balmer et al., 2006). Both forms of this malignancy, hereditary
and sporadic, are associated with somatic loss of function of both
alleles of the tumor suppressor gene RB1. Hereditary forms are
also associated with germline loss of function of one of the RB1
alleles (Knudson, 1971; Cavenee et al., 1983; Friend et al., 1986).
The RB1 protein (pRb) is known to have crucial roles in cell cycle
control and differentiation, being involved in the G1/S transition
via repression of the E2F transcription factor essential for S phase
initiation (Giacinti and Giordano, 2006).
It might be surprising that loss of function of RB1, a cru-
cial component in the control of the cell cycle, has its highest
impact on a small population of cells, namely the cone precur-
sors in the developing retina. However, the highest expression of
pRb in the retina was indeed observed in cone precursors, sug-
gesting a stronger antiproliferative role in these cells (Xu et al.,
2009). It was also demonstrated that MDM2 and NMYC are
highly expressed inmaturing human cone precursors.MDM2 can
abrogate E2F- and ARF-mediated apoptotic responses by inhibit-
ing p53. Using lentiviral short harpin RNA vectors to decrease
MDM2 or NMYC expression, Xu et al. (2009) have demon-
strated impairment in cell proliferation, induction of apoptosis,
and increased proportion of G0/G1 cells. These findings are
consistent with a cone precursor origin of RB and a crucial
role for MDM2 in the development and maintenance of the
tumor.
RB has long been the prototypic “model” cancer, ever since
Knudson’s comparison of the age of diagnosis of bilateral versus
unilateral patients led to his “two-hit” hypothesis for the initia-
tion of cancer (Knudson, 1971). However, these events, although
apparently sufficient to initiate a tumor, are modified by the
presence of numerous additional genetic changes in RB tumors.
Evidence from developing retinal cells indicates that two muta-
tional events are not enough for malignant transformation (Chen
et al., 2004), and an increasing number of studies have suggested
that other hits are associated with RB development. Indeed, sev-
eral genes and pathways have shown functional dysregulation and
misexpression in RB, and pointed to surprising ways in which the
expression of RB1 can be modulated. Here we review the genetics
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and epigenetics of RB with focus on the role of small non-coding
RNAs (microRNAs) and molecular mechanisms involved in the
development and prognosis of this neoplasia.
MICRORNAs AND RETINOBLASTOMA
MicroRNAs (miRNAs) encode small non-coding RNAs that have
been recognized as a large gene class present in most organ-
isms. MicroRNAs are molecules 18–25 nucleotides long that are
produced through two cleavage steps. These steps are accom-
plished by two distinct complexes between an RNA III enzyme
and double-strand RNA-binding domain proteins (DROSHA-
DGCR8 and DICER-TRBP). Mature miRNAs are incorporated
into miRNA-protein complexes that bind to the 3′ untrans-
lated region (3′UTR) of mRNA targets (He and Hannon, 2004;
Zhao et al., 2009). These complexes are referred to as micro-
ribonucleoproteins (miRNPs) or miRNA-induced silencing com-
plexes (miRISCs). The best characterized components of miRNPs
are proteins of the Argonaute family (Peters and Meister, 2007;
Filipowicz et al., 2008). The binding ofmiRNA-protein complexes
to mRNAs species inhibits translation or destabilize the target
transcript resulting in the downregulation of the protein product
encoded by the respective mRNA (Figure 1).
MicroRNAs are expressed in a tissue-specific and develop-
mental stage-specific manner, providing an additional layer of
complexity in the regulation of gene expression. Through the par-
allel modulation of the expression of target transcripts, miRNAs
can coordinately alter many different signaling pathways and cel-
lular processes such as proliferation, differentiation, or apoptosis.
Accordingly, the control of critical targets by miRNAs has mul-
tiple implications in cancer (He and Hannon, 2004; Bueno and
Malumbres, 2011).
At least 10% of the human genome is regulated in a cell
cycle-dependent manner (Iyer et al., 1999) and miRNAs are
known to be functionally integrated into many crucial cell cycle
control pathways. Many miRNAs are antiproliferative, and this
function may be mediated by control of different mitogenic path-
ways, including the routes that lead to activation of CDKs. A
few miRNAs induce proliferation by targeting CDK inhibitors or
members of the pRB family (Bueno and Malumbres, 2011).
The discovery of differentially expressed miRNAs in human
RB is recent and has been replicated with a variety of tech-
niques. These include real time qPCR, microarray, and deep
sequencing. Altogether, several several miRNAs are emerg-
ing as candidate components of oncogene and tumor sup-
pressor networks in RB. Table 1 shows some differentially
expressed miRNAs in RB tumor when compared to normal
retina.
The majority of differentially expressed miRNAs in RB
were also described in association with other cancers. miR-
373, for instance, was identified in a functional screen for
miRNAs that promote cell migration in vitro (Huang et al.,
2008), and its prometastatic potential has been validated in
FIGURE 1 | Biogenesis of microRNAs (miRNAs). miRNA genes are
transcribed and the resulting primary transcripts (pri-miRNAs) are
polyadenylated at the 3′ end and capped at the 5′ end. Pri-miRNA molecules
are recognized by the Drosha-DGCR8 complex and trimmed in a
precursor-miRNA (pre-miRNA) that is transported to the cytoplasm by
Exportin-5. In the cytoplasm, Dicer processes the pre-miRNAs and one
miRNA duplex is released from each pre-miRNA. The two strands of the
duplex are separated from each other by the Dicer-TRBP complex and one of
the strands (called mature miRNA) is incorporated into the RNA-induced
silencing complex (RISC) that will target specific mRNAs in a
sequence-dependent manner. The other strand, which is not incorporated
into RISC, is called the miRNA strand and is degraded.
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Table 1 | microRNAs that are differentially expressed in human retinoblastoma.
microRNAs References/Methods
let-7e; miR-513; miR-518c; miR-129; miR-198; miR-320; miR-373; miR-492; miR-494; miR-498; miR-503 Zhao et al., 2009/A
let7a; let-7f; miR-2; miR-7; miR-9; miR-16; miR-17a, miR-20a; miR-25; miR-26a; miR-30b; miR-30d; miR-92a; miR-93a;
miR-96; miR-99b; miR-101; miR-103; miR-106b; miR-124; miR-143; miR-148b; miR-181a; miR-183; miR-216a; miR-217;
miR-378; miR-1246
Conkrite et al., 2011/A
let-7a; let-7b; let-7c; miR-10a; miR-10b; miR-20a; miR-21; miR-28; miR-29b; miR-30a-3p; miR-30b; miR-30c; miR-30d;
miR-99a; miR-99b; miR-100; miR-103; miR-107; miR-124a; miR-125a; miR-125b; miR-133a; miR-136; miR-141; miR-145;
miR-146a; miR-155; miR-181a, miR-181b; miR-182; miR-183; miR-190; miR-191; miR-206; miR-210; miR-222; miR-301;
miR-302a; miR-302b; miR-320; miR-330; miR-335; miR-342; miR-368; miR-373; miR-380-5p; miR-382; miR-423; miR-433;
miR-451; miR-452; miR-491
Li et al., 2012/A
miR-34a Dalgard et al., 2009/B; C
let-7c; let-7i; let-7g; miR-10a; miR-10b; miR-28-5p; miR-29a; miR-29b; miR-29c; miR-34a; miR-34b; miR-34c-5p; miR-96;
miR-99a; miR-100; miR-124; miR-125b; miR-130a; miR-132; miR-135b; miR-137; miR-142-3p; miR-142-5p; miR-149;
miR-181a; miR-182; miR-183; miR-193a-3p; miR-193b; miR-199a-3p; miR-214; miR-224; miR-338-3p; miR-363; miR-374a;
miR-375; miR-376a; miR-505
Jo et al., 2011/A
A, microarray analysis; B, semiquantitative RT-PCR; C, real-time qPCR.
tumor transplantation experiments using breast cancer cells.
Furthermore, miR-373 has been identified as a potential onco-
gene in testicular germ cell tumors (Voorhoeve et al., 2006).
However, it has been proposed that the prometastatic and onco-
genic properties of this miRNA are due to the regulation of
distinct sets of genes (Voorhoeve et al., 2006; Ventura and Jacks,
2009). Zhao et al. (2009) showed that, in RB tumors, miR-
373 expression level was increased compared to normal retina,
suggesting a role in tumor pathway.
TUMOR SUPPRESOR miRNAs IN RETINOBLASTOMA
Members of the let-7 family are among the most widely stud-
ied tumor suppressor miRNAs. The first member of this family
was discovered in the worm C. elegans, where it induces cell
cycle exit and terminal differentiation of a specific cell type at
the transition from larval to adult stages (Reinhart et al., 2000).
Coherent with a role in inhibiting tumor development in humans,
meager expression of multiple members of the let-7 family is
correlated with poor prognosis in lung cancer (Yanaihara et al.,
2006). Functionally, let-7 represses members of the Ras family of
oncogenes (Johnson et al., 2005) as well as HMGA2 and c-Myc
oncogenes (Lee andDutta, 2007; Mayr et al., 2007; Sampson et al.,
2007). In a recent study, reduced expression levels of let-7 were
observed in RB (Mu et al., 2010). Additionally, an inverse correla-
tion between let-7 down-regulation and HMGA2 overexpression
was documented (Mu et al., 2010).
The miR-34 family of miRNAs, located in 1p36, is also asso-
ciated with tumor suppressor functions. Studies have demon-
strated that p53 transcriptionally activates the miR-34 family
(Chang et al., 2007; He et al., 2007; Raver-Shapira et al., 2007).
Additionally, p53-mediated transcriptional activation of miR-34
family members contributes to p53-dependent tumor suppres-
sion through cell cycle arrest and activation of apoptosis (Chang
et al., 2007; He et al., 2007; Raver-Shapira et al., 2007; Tarasov
et al., 2007). Loss or silencing of miR-34a has been identified in
several human cancers, including brain, breast, colorectal, lung,
pancreatic, and prostate; these observations make miR-34a an
attractive microRNA for therapeutic development (Dalgard et al.,
2009). In the two commonly used RB cell lines (Y79 and Weri-
Rb1). miR-34a shows variable expression levels, and it has been
suggested that knockdown of miR-34a by anti-miR molecules
may result in increased RB cell proliferation and chemotherapeu-
tic resistance (Dalgard et al., 2009). These authors also observed
additional RB cell growth inhibition when topotecan was used
combined with miR-34a. This result is in agreement with previ-
ous findings of similar growth inhibition in a combined treatment
using topotecan and the p53 activator nutlin-3 (Laurie et al.,
2006). Altogether, the evidence supports the notion of a tumor
suppressor role for miR-34a in the normal retina.
ONCOGENIC miRNAs IN RETINOBLASTOMA
Several oncogenic miRNAs have also been identified. The
miR17∼92 cluster (OncomiR-1) has been studied in a broad
range of cancers. miR-17∼92 cluster belongs to a highly con-
served family of polycistronic miRNA genes, whose two other
members are the miR-106a∼363 cluster and the miR-106b∼25
cluster (Ventura et al., 2008; Sage and Ventura, 2011). Studies
in mice showed that these three clusters share partially overlap-
ping targets and functions, with miR-17∼92 being essential for
mammalian development. Nevertheless, the relative contribution
of the various miRNAs encoded by the three clusters is poorly
understood (Ota et al., 2004; Olive et al., 2010).
Recurrent focal amplifications of the miR-17∼92 locus were
reported in a significant fraction of diffuse large B-cell lym-
phomas (Ota et al., 2004; Olive et al., 2010), and overexpression
of the six miRNAs encoded by this cluster was observed in a
wide variety of solid and liquid tumors (Ventura et al., 2008).
Mir-17∼92 carries out pleiotropic functions during both normal
development and malignant transformation. It acts to promote
proliferation, inhibit differentiation, increase angiogenesis, and
sustain cell survival (Olive et al., 2010). In RB, miR-17∼92 acts
via proliferation control to promote tumorigenesis, at least in
part via direct suppression of key cell cycle inhibitors such as
p21CIP1 and p57KIP2 (Conkrite et al., 2011). The experiments
www.frontiersin.org December 2012 | Volume 3 | Article 284 | 3
Reis et al. Genetics and epigenetics of retinoblastoma
of Conkrite et al. (2011) suggested that miR-17∼92 synergizes
with loss of Rb family members to promote RB. miR-17∼92
genomic amplifications were observed in murine RB, and high
expression of miR-17∼92 was observed in human RB. However,
while miR-17∼92 was dispensable for mouse retinal develop-
ment, miR-17∼92 overexpression, together with deletion of pRb
and p107, led to rapid emergence of RB with frequent metas-
tasis to the brain. Furthermore, these authors found that dele-
tion of Rb family members led to compensatory up-regulation
of the cyclin-dependent kinase inhibitor p21Cip1. MiR-17∼92
overexpression counteracted p21Cip1 up-regulation, promoted
proliferation, and drove RB formation (Conkrite et al., 2011).
Another study (Nittner et al., 2012) investigated whether the sur-
vival function of miR-17∼92 was applicable to human tumors
that harbor RB1 mutations. In order to address this question,
components of the miR-17∼92 cluster were inactivated using
miRNA inhibitors in the human RB cell lines RBL15, WERI-
RB1, and Y79. Results indicated that miR-17∼92 inactivation
suppresses RB formation in mice, and co-silencing of miR-
17/20a and p53 cooperatively decreases the viability of human
RB cells (Nittner et al., 2012). The authors suggested that RB
cells might be addicted to high levels of miR-17∼20a expres-
sion as a result of a synthetic lethal interaction with both p53
and RB pathways. Together with additional recently reported data
(Olive et al., 2010), these findings identify miR-17 and miR-
20a (from miR17∼92 cluster) as putative therapeutic targets for
the selective prevention and/or treatment of RB (Nittner et al.,
2012).
Studies investigating miRNA expression patterns in different
RB cell lines indicated that the differentially expressed miRNAs
in two RB cell lines show different impact on tumor growth:
SNUOT-Rb1 cell line shows adherent and more rapid growth,
while Y79 cells display non-adherent and slower growth (Jo
et al., 2011). The authors suggested that many targets of the
overexpressed miRNAs in each cell line have specific biological
functions, which would impact RB progression, like cell adhesion,
cell cycle, cell death, and cell division. Interestingly, while some
differentially expressed miRNAs were known as oncogene miR-
NAs, other miRNAs were regarded as tumor suppressor miRNAs
in other tumors (Jo et al., 2011).
Altogether, the data presented by studies in miRNAs and
RB not only provide novel insights into the pathogenesis of
this neoplasia, but also may have therapeutic potential for
decreasing oncogenic activity, increasing tumor suppressive func-
tion, and/or promoting differentiation in a very large group of
cancer patients. Figure 2 shows an overview of the cell cycle
control by microRNAs and some proteins. However, further stud-
ies on in vitro and in vivo activities of specific miRNAs and
their role in normal cell types are required for their reliable
use as a biomarker for risk assessment and as a therapeutic
target.
PROTEIN CODING GENES ASSOCIATED WITH
RETINOBLASTOMA
DIFFERENTIAL GENE EXPRESSION PROFILE IN RETINOBLASTOMA
Recently a great number of studies have documented the dif-
ferential gene expression profile of RB compared to normal
retina. Ganguly and Shields (2010), identified 1116 genes with
increased expression and 837 genes with decreased expression in
RB tumor tissue compared to matched normal retinal tissue from
six individuals. Functional categories of the cognate genes with
the greatest statistical support were cell cycle (309 genes), cell
death (437 genes), DNA replication, recombination and repair
(270 genes), cellular growth and proliferation (464 genes), and
cellular assembly and organization (110 genes). The list included
differentially expressed retinal cone cell-specific markers, indicat-
ing the predominance of cone cells in RB, and supporting the
notion that the latter group of cells may be the cells of origin for
RB (Xu et al., 2009; Ganguly and Shields, 2010).
Ganguly and Shields (2010) suggested that genes differentially
expressed in RB belong mainly to DNA damage response path-
ways, including BRCA1, BRCA2, ATM, ATR, E2F, and CHK1
genes. In addition, the authors suggested the involvement of
additional and novel pathways. These include pathways involved
in aryl hydrocarbon receptor (AHR) signaling, polo-like kinase
and mitosis, and purine metabolism. Molecules AHR, CHK1,
and polo-like kinases are of particular interest because there
are several currently available drugs that target these molecules
(Ganguly and Shields, 2010). Also, AHR forms a complex and
synergizes with pRb to repress E2F-dependent transcription and
cell cycle progression (Puga et al., 2000). This finding suggests an
additional mechanism through which environmental signals can
function to activate pRb. Accordingly, one of the critical functions
of AHR appears to be that it acts as an environmental sensor that,
in the presence of environmental toxicants, binds to pRb, and
signals cell cycle arrest (Puga et al., 2000).
Chakraborty et al. (2007) used microarrays to analyze gene
expression profile of RB, and observed 1004 upregulated, and 481
downregulated genes compared to retina samples from normal
controls. Clusters of differentially expressed genes were identified
on chromosomes 1, 16, and 17. Based on the expression profile,
the authors hypothesized that the PI3K/AKT/mTOR (insulin sig-
naling) pathwaymight be dysregulated in RB. This was supported
by semiquantitative RT-PCR analysis of PIK3CA, AKT1, FRAP1,
and RPS6KB1 genes in RB samples, suggesting that the potential
therapeutic use of known inhibitors of this pathway (Chakraborty
et al., 2007).
An investigation of RB-related genes with shortest path in
a protein–protein interaction network identified a total of 527
genes and ranked them by their betweenness (Li et al., 2012).
The top 119 genes with betweenness greater than 100, and p-value
<0.05 were further analyzed owing to their potential importance
in the regulatory network of RB. Intriguingly, the authors found
genes with no previous association with RB, or that have been
only poorly characterized. These include CDC25C, NOTCH1,
CDC6, PLK3, and VAV1. CDC25C is an important phosphatase
in cell cycle control, particularly for entry into mitosis, and the
increase in CDC25C has been documented in multiple cancers
with poor prognosis (Iguchi et al., 2007). Notch signaling plays
an essential role in the processes of embryogenesis and cellular
differentiation. It has been reported that elevated Notch signaling
and epigenetic silencing of RB1 in Drosophila can lead to tumori-
genesis (Axelson, 2006). CDC6 is an essential regulator of DNA
replication in eukaryotic cells. Its main function is the assembly
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FIGURE 2 | An overview to cell cycle control by microRNAs and some key proteins. S indicates the S-phase; M indicates the mitosis; G1 and G2 indicate
transition phases of the cell cycle whereas G0 indicates quiescent cells.
of pre-replication complexes at origins of replication during the
G1 phase of the cell division cycle. Moreover, CDC6 also plays
critical roles in the activation and maintenance of G1-S check-
point, as an essential regulator of initiation of DNA replication.
Elevated levels of CDC6was observed inmany human cancer cells
(Li et al., 2012). PLK3 is a member of the Polo-like kinases family
that becomes phosphorylated following DNA damage or mitotic
spindle disruption (Bahassi El et al., 2002). Some studies have
shown that PLK1 expression is elevated in many cancers includ-
ing non-small cell lung cancer, head and neck cancer, colorectal
cancer, and others. PLK1 gene and protein expression have been
regarded as new prognostic markers for many types of malignan-
cies, as well as a potential target for cancer therapy (Takai et al.,
2005). Proto-oncogene VAV1 is a member of the Dbl family of
guanine nucleotide exchange factors (GEF) for the Rho family
of GTP binding proteins. It has been shown that VAV1 is ectopi-
cally expressed in a large number of cancers, including pancreatic
adenocarcinoma, neuroblastoma, melanoma, and B-cell chronic
lymphocytic leukemia (Li et al., 2012).
CANDIDATE ONCOGENES AND TUMOR SUPPRESSOR GENES
IN RETINOBLASTOMA
RB represents one of the rare cancers in which the initiating
genetic lesion (RB1 loss of function) is known, and provides an
excellent system in which to identify new genes, which may, like
RB1, have broad importance for cancer development (Corson and
Gallie, 2007). Evidence for additional events (termed M3 to Mn
in keeping with Knudson’s nomenclature) in RB, along with epi-
genetic modification are being documented at a fast pace. Studies
performing karyotype analyses, comparative genomic hybridiza-
tion (CGH) and microarray-based CGH (aCGH) showed recur-
rent Mn events composed by chromosomal gains and losses
(Corson and Gallie, 2007). These recurrent events identify can-
didate oncogenes and tumor suppressor genes that might play
important roles in RB. Accordingly, gain of 1q, 2p, 6p, and 13q,
and loss of 16q were the most frequently observed chromosomal
aberrations. Potential candidate genes included KIF14, MDM4,
MYCN, E2F3, DEK, CDH11; aberrant methylation of MGMT,
RASSF1A, CASP8, and MLH1 genes was also identified (Corson
and Gallie, 2007).
Although the development and/or progression of RB is not
typically associated with TP53 gene mutations (Huang, 1999),
recent studies have suggested that dysregulation or inactivation
of the p53 pathway might also be relevant in RB (Laurie et al.,
2006; de Oliveira Reis et al., 2012). Accordingly, amplification
of two oncogenes associated with p53 regulation, MDM2, and
MDM4, as well as polymorphisms in these genes have been asso-
ciated with RB development and/or survival (Laurie et al., 2006;
de Oliveira Reis et al., 2012). Polymorphisms rs2279744 T>G in
MDM2 and rs116197192 G>A in MDM4, were investigated in
RB patients and compared to controls. The MDM2 rs2279744G
allele was significantly more frequent in controls, pointing to
a possibly protective effect on RB development. However, the
survival of patients who carried a constitutional RB1 muta-
tion was significantly lower with rs2279744TG or GG than with
rs2279744TT genotypes. Presence of the rs2279744G allele and
a constitutional RB1 mutation was six-fold more frequent in
the 0–12 month age group than other age groups at onset of
symptoms. MDM4 rs116197192G allele was present at a signif-
icantly higher frequency in patients suggesting that this allele
might increase the risk of developing RB. Results indicated that
MDM2 and MDM4 polymorphisms might influence develop-
ment and/or survival in RB (de Oliveira Reis et al., 2012). Laurie
et al. (2006) showed that, during retinogenesis, the tumor surveil-
lance pathway mediated by ARF, MDM2, MDM4, and p53 is
activated after loss of pRb. RB1-deficient retinoblasts undergo
p53-mediated apoptosis and exit the cell cycle. Subsequently,
amplification of MDM4 and increased expression of MDM4
are strongly selected for during tumor progression, as a mech-
anism to suppress p53 response in RB1-deficient retinal cells.
Altogether, the data provided evidence that p53 pathway is
inactivated in RB, and that this cancer does not necessarily
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originate from intrinsically death-resistant cells as previously
thought.
Studies using other neoplasias have also contributed to identify
chromosomal regions that contain genes relevant for RB1 regu-
lation. Lee et al. (2007) used human bladder cancer as a model
system to identify clonal genetic hits associated with growth
advantage, tracking the evolution of bladder cancer from intrau-
rothelial precursor lesions. Six putative chromosomal regions
critical for clonal expansion of intraurothelial neoplasia and
development of bladder cancer were identified. In particular, Lee
et al. (2007) identified a 1.34-Mb segment around the RB1 gene
associated with the initial expansion of the neoplasia. This seg-
ment contained additional candidate genes (Figure 3A) that may
contribute to cancer progression; Interesting targets include two
neighbor genes flanking RB1, namely ITM2B and RCBTB2, as
well as P2RY5, which is located inside RB1. Indeed, Lee et al.
(2007) reported that ITM2B and P2RY5 modulated cell survival
andwere silenced bymethylation or pointmutations, respectively.
Their functional loss may contribute to the growth advantage
of cancer derivatives. The authors also showed that homozygous
inactivation of P2RY5 was antecedent to the loss of RB1 during
tumor development, and that nucleotide substitutions in P2RY5
increased cancer risk. Hence, epigenetic alterations that target not
only RB1 but also its flanking genes might significantly contribute
to RB emergence and progression.
METHYLATION IN RETINOBLASTOMA
Greger et al. (1989) were the first to show that CpG 106, which
overlaps the RB1 promoter and exon E1, is methylated in some
RB tumors. This was one of the first hints that promoter methy-
lation of a tumor suppressor gene plays a role in tumorigenesis.
Subsequently, Sakai et al. (1991) investigated methylation marks
at the 5′ end of the RB1 gene in DNA purified from 56 primary
RBs. The study found five tumors with evidence of hypermethy-
lation (Sakai et al., 1991). Later, Ohtani-Fujita et al. (1993) found
that in vitro methylation of the RB1 promoter in a reporter gene
construct reduced gene expression by 92% (Ohtani-Fujita et al.,
1993). Furthermore, they have identified two transcription fac-
tors that did not bind to RB1 when their recognition sequences
were methylated (Ohtani-Fujita et al., 1993). These studies as well
as that of Toguchida et al. (1993), identified high densities of
CpG sequences in a region encompassing exon 1 and in a second
region in intron 2 of the RB1 gene. It was hypothesized that these
regions might be associated with loss of function of the RB1 gene
FIGURE 3 | Chromosome 13 and the RB1 gene (not drawn to scale).
(A) Chromosome 13 and the q14.2 band highlighted in a red square. Inside
q14.2 band are RB1 gene (highlighted in a green square) and flanking genes.
(B) RB1 gene showing exons 1–27. Black boxes are untranslated regions
(UTR) 5′ and 3′. Two promoter regions investigated in methylation studies
are shown inside the 5′UTR. A large number of MSP studies investigated
the essential promoter region, while the MLPA studies investigated part of
these two regions. These regions concentrate a large number of CpG
island, like CpG 106, CpG 42, and CpG 85. (C) A pair of horizontal lines
showing the location of LINE1 repeats in RB1 gene oriented in the sense
direction (top line) and antisense direction (bottom line). Each black bar
represents one LINE1, orange bars represent two LINE1 repeats. The bar
thickness is proportional to the size of the sequence. (D) A pair of horizontal
lines showing the location of ALU repeats in RB1 gene oriented in the
sense direction (top line) and antisense direction (bottom line). Each black
bar represents one ALU repeat, orange bars represent two ALU repeats.
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due to allele specific hypermethylation (Toguchida et al., 1993).
Since then, many studies have documented RB1 promoter methy-
lation (Ohtani-Fujita et al., 1997; Richter et al., 2003; Corson and
Gallie, 2007; Livide et al., 2012), and have shown an epigenetic
component of RB tumorigenesis.
Kanber et al. (2009) have identified novel imprinted loci by
genome wide CpG methylation analysis of DNA from the blood
of patients with methylation disorders. A 1.2 kb CpG island with
parent-of-origin-specific methylation was identified inside intron
2 of the RB1 gene—the segment is methylated on the maternal
chromosome 13 and unmethylated on the paternal chromo-
some 13. This CpG island (CpG 85) serves as a promoter for
an alternative transcript of RB1, which is expressed from the
unmethylated paternal chromosome only. The first exon of this
alternative transcript is E2B, which is spliced onto exon E3.
This feature distinguishes CpG 85 from two other CpG islands
associated with the RB1 gene: CpG 42, which is located a few
kilobases upstream of CpG 85, and CpG 106, which overlaps
the RB1 promoter and exon E1. CpG 42 is biallelically methy-
lated, whereas, CpG 106 is biallelically unmethylated (Buiting
et al., 2010). Figure 3B shows the location of CpGs 106, 42,
and 85 on RB1 gene. If the alternative transcript (RB1) were
expressed in addition to and independently of the regular pater-
nal transcript, then the total level of paternal transcripts should
be higher than that of the maternal transcripts. However, anal-
ysis of parent-of-origin-dependent expression of RB1 transcripts
revealed a 3-fold excess of maternal RB1 mRNA (Kanber et al.,
2009). In mice, which do not have the intronic CpG island, no
parent-of-origin-specific expression imbalance was found, indi-
cating that skewed allelic expression of the human pRb is linked
to the differentially methylated CpG 85. This notion was fur-
ther substantiated by the finding that demethylation of CpG
85 in lymphoblastoid cell lines by 5-aza-20-deoxycytidine treat-
ment resulted in reduced skewing of the allelic RB1 transcripts,
which is to be expected because after loss of CpG 85 methy-
lation the maternal allele resembles the paternal allele (Kanber
et al., 2009). Authors suggested that allele-specific methylation
of CpG 85 affects expression of pRb, probably by transcriptional
interference (a mechanism in which the transcription of one
gene has a suppressive influence on the transcription of another
gene). It is plausible that differential penetrance and variation
of age at diagnosis, which have been observed in patients with
hereditary and non-hereditary RB, respectively, are a consequence
of imprinted expression. The direction of the imprint imposed
on RB1 gene is the same as that of the maternally expressed
CDKN1C gene, which operates upstream of RB1 (Kanber et al.,
2009).
Interestingly, analyses by Kanber et al. (2009) suggested that
CpG 85 is part of a 4.5 kb region with a high sequence iden-
tity (87%) to exon 4 of KIAA0649, a four-exon gene in segment
9q34.3. The four small (∼300 bp) CpG islands present in exon
4 of KIAA0649 appear to have evolved into two CpG islands
(CpG 85 and CpG 42) following integration into the RB1 gene
(retrotransposition event). Specifically, CpG 85, which spans
1.2 kb, corresponds to the small islands CpG 19 and CpG 17 at
the KIAA0649 locus, which only contain 229 bp and 209 bp,
respectively (Kanber et al., 2009). Other transposition events are
important for the stability and expression of the RB1 gene. One
case is a 799-bp deletion in the intron 2 of RB1. It was identified
in a group of brain tumors and probably emerges due to a homol-
ogous recombination between two Alu repeats (Rothberg et al.,
1997). Figures 3C,D show LINE1 and ALU repeats distribution
in the RB1 gene.
The methylation status of other genes has also been studied in
RB. Analysis of p16INK4A promoter methylation in RB showed
hypermethylation in most patients with p16INK4A downregu-
lation, and in their parents (Indovina et al., 2010; Saxena and
Kaur, 2011). The finding that p16INK4A was downregulated
both in RB patients and their parents suggests that this alter-
ation could be a novel heritable susceptibility marker to RB.
The observation that p16INK4A downregulation seems to be
due to its promoter hypermethylation opens the way for the
development of new preventive and therapeutic strategies using
demethylating agents (Indovina et al., 2010; Saxena and Kaur,
2011).
Liu et al. (2009) investigated the methylation status of
RASSF1A or DAPK promoter in 28 RB tissues, normal retinal
tissues from five donor cadaver eyes, nine peripheral blood sam-
ples of RB patients, and normal-peripheral blood samples from
five healthy volunteers matched on age and sex by methylation-
specific PCR (MSP). The authors found that the percentage of
RASSF1A hypermethylation in RB tissues (60.7%) was statisti-
cally higher (p < 0.01) than in the normal retinal tissue (0%)
and in the adjacent non-neoplastic retinal tissue (17.9%). The
hypermethylation percentage in unilateral RB group was also
higher than in the bilateral RB group. On the other hand, DAPK
promoter hypermethylation was not found in any RB tumor or
peripheral blood sample. RASSF1A is a tumor suppressor whose
inactivation is implicated in the development of many human
cancers (Liu et al., 2009). Its methylation status and role in RB
was demonstrated previously by Harada et al. (2002), who found
RASSF1A promoter methylation in 59% of RB tumors (Harada
et al., 2002).
Recently, Zhang et al. (2012) identified the SYK gene as a
potentially important oncogene in RB. This gene is the fifth
most significant gene identified by their analysis and the only
kinase gene that is upregulated. SYK regulates immunomodula-
tory signaling, it is expressed in the haematopoietic system, and
has been implicated in several haematologic malignancies (Chen
et al., 2008; Feldman et al., 2008; Hahn et al., 2009; Young et al.,
2009; Zhang et al., 2012). Interestingly, this protein has no known
function in the developing visual system, with retinal progeni-
tor cells and retinal neurons expressing little or no SYK (Zhang
et al., 2012). Moreover, no recurrent genetic lesions in SYK had
been identified by WGS or SNP array analysis to suggest that
this gene drives RB tumorigenesis. Epigenetic profiles, however,
showed profound changes in SYK relative to that observed in
normal retinoblasts. SYK is required for tumor cell survival, and
inhibition of SYK with a small-molecule inhibitor caused the
degradation of MCL1 and caspase-mediated cell death in RB cells
in culture and in vivo (Zhang et al., 2012).
Livide et al. (2012) used Methylation-specific Multiplex
Ligation-dependent Probe Amplification (MS-MLPA) to inter
rogate epigenetic and copy number variation in 12 paraffin
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embedded RB tissue samples. The authors identified promoter
hypermethylation in seven genes (proportion of hypermethylated
tumors is shown in parenthesis): MSH6 (50%), CD44 (42%),
PAX5 (42%), GATA5 (25%), TP53 (8%), VHL (8%), and GSTP1
(8%). Also, the study replicated the previously reported hyper-
methylated genes: MGMT (58%), RB1 (17%), and CDKN2 (8%).
These genes belong to key pathways, including DNA repair, pRB
and p53 signaling, transcriptional regulation, protein degrada-
tion, cell–cell interaction, cellular adhesion, andmigration. In the
same study, a total of 29 copy number changes (19 duplications
and 10 deletions) were identified. Interestingly, they have found
deletions of the following oncosuppressor genes that might con-
tribute to drive RB tumorigenesis: TP53, CDH13, GATA5, CHFR,
TP73, and IGSF4 (Livide et al., 2012). Figure 3B shows a graphi-
cal presentation of RB1 gene with the main promoter regions and
CpG islands investigated in methylation studies.
Finally, parent-of-origin effects have been reported in human
phenotypes associated with mutations in RB1. These include
parental effects on the differential penetrance and age of onset
in RB, and an excess of first somatic mutations on pater-
nal alleles in sporadic osteosarcoma (Toguchida et al., 1989;
Klutz et al., 2002; Richter et al., 2003; Schuler et al., 2005).
Altogether, the evidence points to a greater role for epigenetic
alterations in RB. Nevertheless, recent advances in genomics and
epigenomics have made it possible to study RB in novel ways.
Microarray and sequencing technologies in association with mul-
tiple complementary technologies, including CGH, serial analy-
sis of gene expression (SAGE), chromatin immunoprecipitation
(ChIP), proteomics, and deep sequencing have been used to study
all aspects of cancer biology. Their judicious application might
help uncover the molecular mechanism of cancer development
and have an impact on diagnosis, prognosis, drug responses, and
new therapeutic approaches in cancer. Combining the results
of these multidisciplinary approaches will contribute to a better
biological understanding of RB and an improved clinical man-
agement of RB patients. RB1 loss has long been recognized as
the causative genetic alteration underlying RB but it is increas-
ingly evident that other genetic and epigenetic alterations are
also required for the tumor to develop. Recent findings highlight
how comprehensive genetic and epigenetic analyses of tumors can
be integrated to shed light on the mechanisms underlying the
progression of RB following RB1 inactivation.
CONCLUSIONS
RB represents one of the rare cancers in which the initiating
genetic lesion (RB1 loss of function) is known. Yet, the genetic and
epigenetic complexity of RB is widely appreciated, and evidenced
by the intricate network of cellular and epigenetic components
that modulate RB1 expression. These include transcription fac-
tors and chromatin-modifying proteins that target the RB1 locus.
This complexity is also manifested in the structure of the RB1
locus itself: it includes numerous repetitive DNA segments and
retrotransposon insertion elements, some of which are actively
transcribed from the RB1 locus. Evidence indicates that some of
these repetitive elements are targeted in spurious recombination
events that cause RB1 loss of function. Furthermore, a number of
other genes and miRNA targets have also been implicated in the
progression and severity of RB and other cancers. Further com-
plexity emerges from the network of genes, miRNAs, and other
small RNAs whose functions modify RB1 mRNA abundance and
RB1 protein availability. These include not only protein-coding
genes in the immediate vicinity of RB1 but also miRNAs and
other genes located elsewhere in the genome. Altogether, we con-
clude that RB1 loss of function represents the tip of an iceberg
of events that determine RB development, progression, severity,
and disease risk. Comprehensive assessment of personalized RB
risk will require genetic and epigenetic evaluations beyond RB1
protein coding sequences.
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